EBS Q4 2021 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q4 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$723M+24.0% YoY

Gross Profit

$428M59.1% margin

Operating Income

$277M38.4% margin

Net Income

$189M26.2% margin

EPS (Diluted)

$3.50

QoQ Revenue Growth

+119.8%

Cash Flow

Operating Cash Flow

$329M

Free Cash Flow

$282M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$3.0B

Total Liabilities

$1.3B

Stockholders' Equity

$1.6B

Cash & Equivalents

$576M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$723M	$583M	+24.0%
Gross Profit	$428M	$356M	+20.2%
Operating Income	$277M	$258M	+7.5%
Net Income	$189M	$185M	+2.1%

Revenue Segments

Product

$434M60%

Contract Development And Manufacturing

$218M30%

Contracts and Grants

$71M10%

Geographic Segments

UNITED STATES

$433M66%

Non-US

$221M34%